"Israel sees 70% spike in number of seriously ill COVID patients within a week"; see UK graph; go back to prior substacks, we have been warning about this, e.g. Vanden Bossche, we theorized
by Paul Alexander
that sub-optimal non-sterilizing non-neutralizing vaccinal antibodies (Abs) bind to the spike but not eliminate, yet enhances/facilitates infection in vaxxed person, & soon we will see serious disease
Most if not all Israel is vaccinated and many boosted. The UK and Scottish data told us that the vaccinated, especially the double and triple vaccinated (over 50) are at increased risk of infection, hospitalization, and death.
I present the Israel case graph as of today and also the UK case graph as of today, both are showing rises in infection/cases (new wave).
The issue is that the same vaccinal Abs that enhance and facilitate infection in the upper respiratory tract (URT), have been blocking severe disease in the lower respiratory tract (LRT) deep inside the lung. GVB is prescient in this.
That is why we were seeing at first when Omicron emerged, a very strange situation we never saw before where a virus could do both things, cause infection yet mild illness. We even thought OMI was nature’s gift with mild illness. We spoke about this changing as the sub-optimal vaccinal immune pressure would cause the variants to overcome the pressure and we would shift from blocking illness in the LRT (transfection from infected to uninfected cells) to severe disease. Could this now be happening in Israel? I don’t know. We thought that it would happen in one of the most vaccinated nations. Could this be the beginning of a very dangerous situation we spoke about prior? Or is this the usual deaths that emerge 2-3 weeks post infection/case peak (death curve)? All the same, Israel is experiencing some trouble. Why? Near 100% vaccinated.
These vaccines are causing a serious problem.
See paper below by Yahi et al. as a concern for ADE in people receiving vaccines based on the original Wuhan strain spike sequence (either mRNA or viral vectors). Under these circumstances, second generation vaccines with spike protein formulations lacking structurally-conserved ADE-related epitopes should be considered. Yahi et al.’s research demonstrated in the case of the Delta variant (and certainly now in Omicron BA 4 & BA 5 sub-variants), neutralizing (blocking) antibodies have a decreased affinity for the spike protein, whereas facilitating or enhancing (non-neutralizing) antibodies displayed a pronounced increased affinity for the spike protein.